CY1119930T1 - Λευκολεκτινες και χρησεις αυτων - Google Patents

Λευκολεκτινες και χρησεις αυτων

Info

Publication number
CY1119930T1
CY1119930T1 CY20181100201T CY181100201T CY1119930T1 CY 1119930 T1 CY1119930 T1 CY 1119930T1 CY 20181100201 T CY20181100201 T CY 20181100201T CY 181100201 T CY181100201 T CY 181100201T CY 1119930 T1 CY1119930 T1 CY 1119930T1
Authority
CY
Cyprus
Prior art keywords
polypeptide
whiteholders
lectin
antibodies
animal
Prior art date
Application number
CY20181100201T
Other languages
English (en)
Inventor
Bernt Th. Walther
Mirushe Miftari
Original Assignee
Leukolect As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukolect As filed Critical Leukolect As
Publication of CY1119930T1 publication Critical patent/CY1119930T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα πολυπεπτίδιο, που περιγράφεται ως μια λεκτίνη, στην κωδικεύουσα αλληλουχία νουκλεϊκού οξέος αυτού και σε αντισώματα προς το πολυπεπτίδιο και στη χρήση τους σε διάφορες ιατρικές εφαρμογές, ιδιαίτερα για τη θεραπεία ή πρόληψη μιας αυτοάνοσης διαταραχής, μιας φλεγμονώδους διαταραχής ή κατεστραμμένου δέρματος σε ένα ζώο.
CY20181100201T 2008-10-29 2018-02-21 Λευκολεκτινες και χρησεις αυτων CY1119930T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819883.0A GB0819883D0 (en) 2008-10-29 2008-10-29 Product and uses
PCT/GB2009/002569 WO2010049688A1 (en) 2008-10-29 2009-10-29 Leukolectins and uses thereof

Publications (1)

Publication Number Publication Date
CY1119930T1 true CY1119930T1 (el) 2018-12-12

Family

ID=40134057

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100201T CY1119930T1 (el) 2008-10-29 2018-02-21 Λευκολεκτινες και χρησεις αυτων

Country Status (20)

Country Link
US (2) US9260498B2 (el)
EP (1) EP2358745B1 (el)
JP (1) JP5539372B2 (el)
KR (1) KR101448573B1 (el)
CN (1) CN102203127B (el)
AU (1) AU2009309477B2 (el)
BR (1) BRPI0920101B1 (el)
CA (1) CA2741823C (el)
CL (1) CL2011000947A1 (el)
CY (1) CY1119930T1 (el)
DK (1) DK2358745T3 (el)
ES (1) ES2658966T3 (el)
GB (1) GB0819883D0 (el)
MX (1) MX2011004483A (el)
NO (1) NO2358745T3 (el)
NZ (1) NZ592911A (el)
PT (1) PT2358745T (el)
RU (1) RU2528860C2 (el)
WO (1) WO2010049688A1 (el)
ZA (1) ZA201103456B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007202D0 (en) 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201110777D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
PL2691069T3 (pl) * 2012-01-23 2017-03-31 Restorsea, Llc Kosmetyk
KR102134938B1 (ko) * 2012-12-21 2020-07-17 아쿠아 바이오 테크놀로지 에이에스에이 어류 부화액으로부터의 화장료 조성물
GB201223330D0 (en) * 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses
EP3091961A4 (en) 2013-12-13 2017-11-15 Restorsea, LLC Exfoliative hair retention-promoting formulation
EP3142633A1 (en) 2014-05-16 2017-03-22 Restorsea, LLC Biphasic cosmetic
RU2658781C1 (ru) * 2017-12-28 2018-06-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид, обладающий противоопухолевой активностью
AU2019282825A1 (en) * 2018-06-07 2020-12-10 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
US11497209B2 (en) * 2019-06-28 2022-11-15 1283581 Bc Ltd Compositions, methods, and applications of a synthetic surfactant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219905D0 (en) 1992-09-19 1992-11-04 Univ Liverpool Lectins
WO1994011497A1 (en) 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins
NO314594B1 (no) * 1997-12-11 2003-04-14 Aqua Bio Technology As Ikke-selvdegraderende endoprotease, fremgangsmåte for fremstilling samt anvendelser av denne
JP2002516670A (ja) 1998-05-27 2002-06-11 ラウラス エイエス Ｐｋａシグナリング経路のタンパク質活性を変化させる方法
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7510850B2 (en) * 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
KR20070079596A (ko) * 2007-05-10 2007-08-07 김선일 피부질환 치료 보조 기능성 화장료 조성물
GB201007202D0 (en) * 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
KR102134938B1 (ko) * 2012-12-21 2020-07-17 아쿠아 바이오 테크놀로지 에이에스에이 어류 부화액으로부터의 화장료 조성물
GB201223330D0 (en) * 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses

Also Published As

Publication number Publication date
US20110280882A1 (en) 2011-11-17
JP2012506714A (ja) 2012-03-22
US20160151454A1 (en) 2016-06-02
BRPI0920101B1 (pt) 2021-11-23
NO2358745T3 (el) 2018-04-28
CA2741823A1 (en) 2010-05-06
KR20110095274A (ko) 2011-08-24
AU2009309477B2 (en) 2014-12-18
PT2358745T (pt) 2018-02-28
CN102203127A (zh) 2011-09-28
EP2358745B1 (en) 2017-11-29
KR101448573B1 (ko) 2014-10-10
EP2358745A1 (en) 2011-08-24
ES2658966T3 (es) 2018-03-13
CL2011000947A1 (es) 2011-08-05
CN102203127B (zh) 2019-05-28
DK2358745T3 (en) 2018-03-05
RU2011121616A (ru) 2012-12-10
CA2741823C (en) 2018-11-20
WO2010049688A1 (en) 2010-05-06
BRPI0920101A2 (pt) 2016-08-09
GB0819883D0 (en) 2008-12-03
AU2009309477A1 (en) 2010-05-06
US9260498B2 (en) 2016-02-16
ZA201103456B (en) 2012-08-29
MX2011004483A (es) 2011-09-21
NZ592911A (en) 2013-02-22
RU2528860C2 (ru) 2014-09-20
JP5539372B2 (ja) 2014-07-02
US10124034B2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
CY1119930T1 (el) Λευκολεκτινες και χρησεις αυτων
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CY1118120T1 (el) Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων
CY1116962T1 (el) Ανθρωπινες λευκολεκτινες και χρησεις αυτων
CY1119789T1 (el) Cgrp αντισωματα
CY1120177T1 (el) Φλαγκελλινη roseburia και ανοσορυθμιση
CY1121971T1 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1122564T1 (el) Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1116288T1 (el) Tnfsf απλης αλυσου μορια
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1114820T1 (el) Νεες ανοσοενισχυτικες ενωσεις βασιζομενες σε φλαγκελλινη και χρηση αυτων
CY1119760T1 (el) Χρηση τ κυτταρων τροποποιημενων απο χιμαιρικο υποδοχεα αντιγονου για τη θεραπευτικη αγωγη καρκινου
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
CY1115980T1 (el) Υδροπηκτες πολυμερων και χρηση αυτων
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων